Artwork

Indhold leveret af Thermo Fisher. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Thermo Fisher eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Putting Patients First: The Benefits of Decentralized Clinical Trials

26:05
 
Del
 

Manage episode 353516232 series 2557441
Indhold leveret af Thermo Fisher. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Thermo Fisher eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Decentralized clinical trials aim to reduce patient burden. Decentralized clinical trials can help make research more patient-centric. Tim explains the role of decentralization, "It's fair to say that that change management component is absolutely critical in terms of the decentralized adoption, and I think, when I look ahead in terms of decentralization, I see an amazing landscape for patients and the partnerships with EmVenio and also the kind of opportunities Thermo Fisher Scientific has in really driving forward unique and collaborative solutions for the better of the patient and really focusing on reducing that patient burden."

We need to make clinical trials more patient-centric. Patient-centricity is key when it comes to improving participation in clinical trials and clinical research progress overall. Tim says, "As an industry, we talk about patient-centricity and I think we embrace significant patient-centricity by taking a research site with all the research professionals on board to the patient's home."

Representation in clinical trials matters. Diversity is vital to preventing and treating diseases across race and gender. Thad says, "A couple of stats recently — there was one study we supported where of the 2,500 patients that EmVenio enrolled, 65% were from underrepresented populations, and so it really showed that value there. And what we're seeing more broadly is that across the studies we support, greater than 40% of the patients we're working with come from minority populations. And so, to contrast that against industry stats of around 10% to 20% as an average, we're offering more than double the ability to reach these populations that otherwise don't have access. So I think what we're seeing is that the results are really bearing on the value that we're bringing together."

  continue reading

39 episoder

Artwork
iconDel
 
Manage episode 353516232 series 2557441
Indhold leveret af Thermo Fisher. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Thermo Fisher eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Decentralized clinical trials aim to reduce patient burden. Decentralized clinical trials can help make research more patient-centric. Tim explains the role of decentralization, "It's fair to say that that change management component is absolutely critical in terms of the decentralized adoption, and I think, when I look ahead in terms of decentralization, I see an amazing landscape for patients and the partnerships with EmVenio and also the kind of opportunities Thermo Fisher Scientific has in really driving forward unique and collaborative solutions for the better of the patient and really focusing on reducing that patient burden."

We need to make clinical trials more patient-centric. Patient-centricity is key when it comes to improving participation in clinical trials and clinical research progress overall. Tim says, "As an industry, we talk about patient-centricity and I think we embrace significant patient-centricity by taking a research site with all the research professionals on board to the patient's home."

Representation in clinical trials matters. Diversity is vital to preventing and treating diseases across race and gender. Thad says, "A couple of stats recently — there was one study we supported where of the 2,500 patients that EmVenio enrolled, 65% were from underrepresented populations, and so it really showed that value there. And what we're seeing more broadly is that across the studies we support, greater than 40% of the patients we're working with come from minority populations. And so, to contrast that against industry stats of around 10% to 20% as an average, we're offering more than double the ability to reach these populations that otherwise don't have access. So I think what we're seeing is that the results are really bearing on the value that we're bringing together."

  continue reading

39 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning